Theravance, Inc.: Positive Results in COPD Study Trigger $10M Payment from GlaxoSmithKline (JOBS)

SAN FRANCISCO (Thomson Financial) - Theravance Inc. late Monday said positive results from a Phase II study of the investigational compound GSK961081 triggered a milestone payment of $10 million from GlaxoSmithKline.